NovaBay Names Keith Bley As Senior Vice President Of Product Development

Behzad Khosrovi Retires After Ten-Year Career at NovaBay

EMERYVILLE, Calif., March 11, 2013 (GLOBE NEWSWIRE) -- NovaBay ^® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides ^® , today announced that Keith R. Bley, Ph.D., has joined NovaBay as Senior Vice President of Product Development, effective March 4 ^th 2013.

Dr. Bley has more than 20 years of experience in the pharmaceutical industry, management positions with increasing responsibility in research and product development.

Before joining NovaBay, Dr. Bley worked as consultant to various pharmaceutical companies in the San Francisco Bay Area, assisting these companies with a wide range of drug development activities. Prior to his consulting work, Dr. Bley was the Senior Vice President for Nonclinical Research and Development at NeurogesX, Inc. for over ten years. While at NeurogesX, Dr. Bley supported all phases of drug development and built a thorough knowledge of FDA regulations and international regulatory requirements.

Prior to his work at NeurogesX, Dr. Bley worked as Research Manager for Roche Pharmaceuticals and Syntex Corporation.

Dr. Bley received his Ph.D. in Cellular and Molecular Physiology from Yale University. He also earned a masters degree in philosophy from Columbia University and his Bachelors in Philosophy (with Honors) from the Catholic University of America in Washington, D.C.

"We are very excited to welcome Keith on board to NovaBay," said Dr. Ron Najafi, Chairman and Chief Executive Officer. "We believe he brings valuable regulatory expertise both in the U.S. and abroad. Keith has worked on topical therapies, and understands the unique challenge they can represent. We are confident that he will contribute significantly to the NovaBay management team as we and our partners continue moving our lead Aganocide compound, NVC-422 or auriclosene, through three Phase 2 trials."

1 2 3 Next › Last »